Citations 0
Poster Presentations: American Head and Neck Society
August 2006

P015 Phase 1: Update of Weekly Docetaxel, Cisplatin, Daily Celecoxib, Concurrent Radiotherapy in Advanced Head and Neck Cancer

Author Affiliations

Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006

Arch Otolaryngol Head Neck Surg. 2006;132(8):869. doi:10.1001/archotol.132.8.869-a

Objectives: Cyclooxygenase-2 (COX-2) overexpression in locally advanced head and neck cancer and preclinical benefit for COX-2 inhibitors with radiotherapy (RT) led us to study weekly doublet chemotherapy, daily radiotherapy, and celecoxib. Follow-up data on response and tolerability at a median of 20.5 months are presented.

Methods: Eligibility: stage III or IV squamous cell cancer of oral cavity, oropharynx, hypopharynx, larynx; performance status 0, 1, 2; adequate hepatic, hematologic, renal function; and no prior radiotherapy/chemotherapy for this site. Treatment: weekly docetaxel (T), 12.5 mg/m2, and cisplatin (P), 20 mg/m2 intravenously, on day 1 for 6 weeks; and RT, single fraction, on days 1-5 for 7 weeks or to total standard dose (70 Gy); and celecoxib (C), 400 twice daily by mouth. Feeding tubes were placed prophylactically.

First Page Preview View Large
First page PDF preview
First page PDF preview